PMN — ProMIS Neurosciences Income Statement
0.000.00%
Last trade - 00:00- $20.92m
- $7.60m
- 14
- 61
- 18
- 21
Annual income statement for ProMIS Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.001 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.22 | 8.29 | 22.1 | 14.3 | 16.8 |
| Operating Profit | -4.22 | -8.29 | -22.1 | -14.3 | -16.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.22 | -9.79 | -18.1 | -13.2 | 2.78 |
| Net Income After Taxes | -4.22 | -9.79 | -18.1 | -13.2 | 2.78 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.22 | -9.79 | -18.1 | -13.2 | 2.78 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.22 | -9.79 | -18.1 | -13.2 | 2.78 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.887 | -1.69 | -2.58 | -1.07 | 0.105 |